← Back to Clinical Trials
Recruiting NCT05117424

NCT05117424 CArdioMetabolism and Atherosclerotic PlaqUe progreSsion

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05117424
Status Recruiting
Phase
Sponsor Ruijin Hospital
Condition Coronary Artery Disease
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2017-01-01
Primary Completion 2025-12-31

Trial Parameters

Condition Coronary Artery Disease
Sponsor Ruijin Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 3,000
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2017-01-01
Completion 2025-12-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.

Eligibility Criteria

Inclusion Criteria: * Age 18-80 years * Established coronary artery disease or metabolic disorders, including: 1. Type 2 diabetes diagnosed by one of the following criteria: HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents 2. Prediabetes 3. Obesity 4. Chronic kidney disease 5. Hyperuricemia 6. Dyslipidemia Exclusion Criteria: * Severe liver failure (Child-Pugh grade B to C) * Severe anemia (hemoglobin \< 60g/L) * Familial hypercholesterolemia * Active malignant tumor * Active autoimmune diseases on corticosteroids * Acute or chronic infection * Life expectancy \< 1 year

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology